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Introduction

Hypothesis

Coronary heart disease is the leading cause of death worldwide, and is primarily attributable to the
detrimental effects of tissue infarct after an ischemic insult. The most effective therapeutic
intervention for reducing infarct size associated with myocardial ischemia injury is timely and
effective reperfusion of blood flow back to the ischemic heart tissue. However, the reperfusion of
blood itself can induce additional cardiomyocyte death that can account for up to 50% of the final
infarction size. Currently, there are no effective clinical pharmacologic treatments to limit
myocardial ischemia reperfusion (MI/R) injury in heart attack patients [1]. Reperfusion injury is
initiated by decreased endothelial-derived nitric oxide (NO) which occurs within 5 min of
reperfusion [2], and may in part be explained by PKC II mediated activation of NADPH
oxidase, which occurs upon cytokine release during MI/R [3]. PKC II activity is increased in
animal models of MI/R and known to exacerbate tissue injury [4,5]. PKC II is known to increase
NADPH oxidase activity in leukocytes, endothelial cells and cardiac myocytes via phox47
phosphorylation, and decrease eNOS activity via phosphorylation of Thr 495 [6,7,8]. NADPH
oxidase produces superoxide (SO) and quenches endothelial derived NO in cardiac endothelial
cells. Moreover, PKC II phosphorylation of p66Shc at Ser 36 leads to increased mitochondrial
reactive active oxygen species (ROS) production, opening of the mitochondrial permeability
transition pore (PTP), and proapoptotic factors leading to cell death and increased infarct size [9]
(fig 1). Therefore, using a pharmacologic agent that inhibits the rapid release of PKC II mediated
ROS, would attenuate endothelial dysfunction and downstream proapoptotic pathways when
given during reperfusion and should be an ideal candidate to attenuate MI/R injury.
In the current study, we generated MI/R injury by inducing global ischemia for 30 min. in
isolated perfused rat hearts followed by 45 or 90 min reperfusion. A cell permeable PKC II
peptide inhibitor (10- 20 μM) was given at the beginning of reperfusion for five minutes. Postreperfused cardiac function and infarct size were measured and compared to untreated control I/R
hearts. We found that PKC II peptide inhibitor treated I/R hearts exhibited significantly
improved post-reperfused cardiac function and reduced infarct size compared to control I/R
hearts. In addition, the use of PKC II peptide inhibitor (10-20 μM) correlated with the inhibition
of SO release from isolated leukocytes (poster # P168). These findings suggest that PKC II
activation contributes to reperfusion injury and PKC II peptide inhibitor may mitigate
reperfusion injury by inhibiting ROS release.

We hypothesize that PKC II peptide inhibitor will improve postreperfused cardiac function and
reduce infarct size in isolated perfused rat hearts (ex vivo) subjected to global I/R compared to
non-drug control I/R hearts in both MI(30min)/R(45min) & MI(30min)/R(90min) studies.

ε

Methods
Isolated Rat Heart Preparation
Male Sprague Dawley (SD) rats (275-325g) were anesthetized i.p. (pentobarbital sodium 60
mg/kg and 1,000U of sodium heparin). Hearts were rapidly excised and perfused at a constant
pressure of 80 mm Hg with a modified physiological Krebs’ buffer aerated with 95% O2-5% CO2
maintained at 37oC and pH 7.3-7.4 by Langendorff preparation. Hearts were subjected to 15min
of baseline perfusion, 30min of ischemia, and a 45min or 90 min reperfusion period. 5ml of
plasma (control I/R hearts), or plasma containing cell-permeable PKC II peptide inhibitor (NMyr-SLNPEWNET, MW=1300 10 - 20μM Genemed Synthesis Inc. San Antonio TX) were
infused during the first 5min of reperfusion by a side arm line proximal to the heart inflow at a
rate of 1ml/min. Coronary flow, left ventricular developed pressure (LVDP), maximal and
minimal rate of LVDP (+dP/dtmax and –dP/dtmin ), and heart rate were taken every 5min during
baseline and reperfusion using a flow meter (T106, Transonic Systems, Inc., Ithaca, NY) and
pressure transducer (SPR-524, Millar Instruments, Inc., Houston, TX), respectively. Data were
recorded using a Powerlab Station acquisition system (ADInstruments, Grand Junction, CO).
Sham hearts received no drug and were perfused with plasma at the same time point as I/R hearts
and experienced no ischemia. To evaluate tissue viability, the left ventricle was isolated and cross
sectioned into five 2mm pieces from apex to base at the end of the cardiac function experiment.
The pieces were subjected to 1% triphenyltetrazolium chloride (TTC) staining for 15min at 37oC
to detect infarct size (viable tissue stained red, infarct left unstained (white)). Infarct size was
expressed as the percentage of dead tissue to the total tissue weight.
Statistical Analysis
All data in the text and figures are presented as means ± S.E.M. Analysis of variance using post
hoc analysis with the Student-Newman-Keuls test was used for heart function and infarct size in
the MI(30min)/R(90min) study. Student’s t-test was used to compared the two groups in the
MI(30min)/R(45min) study. Probability values of <0.05 are statistically significant.

Figure 3. Time course of LVDP (left) and dP/dt max (right) in sham, control I/R and I/R+PKC βII inhibitor (10
and 20 μM) perfused rat hearts. LVDP and dP/dt max data at initial (baseline) and reperfusion from 0 to 90 min
following 30 min ischemia are shown. I/R+PKC βII inhibitor hearts (10 μM, n=7; 20 μM, n=5) exhibited a
significant improvement in LVDP 66 + 8% and dP/dt max 56 + 8% (20 μM) and 57±7% and 48±5% (10 μM)
compared to control I/R hearts (n=9) that only recovered to 38±6% and 28 ±4% at 90 min post-reperfusion
of initial baseline. Sham hearts maintained cardiac function throughout the experimental protocol (87±9% of
initial LVDP and 89±8% of initial dP/dt max). (*p<0.05; **p<0.01 compared to control).
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Results
Figure 4. Representative TTC stained heart sections displayed above from control I/R and I/R+PKC βII inhibitor
hearts were assessed after cardiac function experiments to determine infarct size. Viable tissue stained red and
infarcted tissue was unstained (white). PKC βII inhibitor hearts displayed a significantly reduced infarct size (29
±3%, 10 uM; 25 ±3%, 20 uM) and compared to control I/R hearts that had an infarct size of 46 ±3,% . Sham
hearts had minimal cell death (<0.05%) at the end of the experimental protocol (data not shown). (*p<0.05 and
**p<0.01 compared to I/R control).

Conclusions
Reperfusion injury following myocardial ischemia has been shown to be a pathologic condition
resulting in myocardial cell death and contractile dysfunction. PKC II peptide inhibitor given at
the beginning of reperfusion significantly improved contractile function and decreased infarct
size compared to I/R control at 45 and 90 min post-reperfusion following 30 min global
ischemia. These data suggest that PKC II inhibition attenuates I/R-induced heart injury and
thereby salvage heart tissue and function when given during reperfusion. These effects may be
related to inhibiting ROS release in MI/R. Therefore, PKC II inhibitor will be an effective
therapeutic tool to ameliorate cardiac contractile dysfunction and tissue damage in heart attack,
coronary bypass, and organ transplant patients.
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Figure 1. Schematic representation of PKC II mediated activation of mitochondrial reactive oxygen species
(ROS) and NADPH superoxide (O2-) release and decreased NO release from eNOS in MI/R (top; adapted from
[9]) and mechanism of action of PKC II inhibitor (PKC II-) (bottom; adapted from [10]). I/R induces cytokine
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Activated PKC II augments ROS release from mitochondria and decreases coupled eNOS activity to promote
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leading to opening of the mitochondrial permeability transition pore (PTP) which in turn leads to consequent
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Figure 2. Time course of LVDP (left) and dP/dt max (right) in control I/R and I/R+PKC βII inhibitor (10 μM)
perfused rat hearts. LVDP and dP/dt max data at initial (baseline) and reperfusion from 0 to 45 min following 30
min ischemia are shown. I/R+PKC βII inhibitor hearts (n=9) exhibited a significant improvement in postreperfused
(45min) LVDP (70±6% of initial) and dP/dt max (55±6% of initial) compared to control I/R hearts (n=9).
Representative TTC stained heart sections displayed above from control I/R and I/R+PKC βII inhibitor hearts were
assessed after cardiac function experiments to determine infarct size. Viable tissue stained red and infarcted tissue
was unstained (white). PKC βII inhibitor hearts displayed a significantly reduced infarct size (24±3% ) compared
to control I/R hearts (43±2% ). All values are expressed as mean ± SEM. *p<0.05 and **p<0.01 from I/R control.
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